Showing results (311-320 of 358) with videos related to

Sort By:
Pageof 36
Nature Communications|January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B Johnson, Monica V Estrada, Roberto Salgado, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Bioinformatics (Oxford, England)|December 6, 2022
Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphsNick Strayer, Siwei Zhang, Lydia Yao, et al.
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Plant, Cell & Environment|January 3, 2017
Identification of mega-environments in Europe and effect of allelic variation at maturity E loci on adaptation of European soybeanAlena K Kurasch, Volker Hahn, Willmar L Leiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast CancerLuigi Formisano, Kimberly M Stauffer, Christian D Young, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Science Translational Medicine|April 15, 2016
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceJustin M Balko, Luis J Schwarz, Na Luo, et al.
Science Translational Medicine|March 13, 2020
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitorsJohanna M Schafer, Brian D Lehmann, Paula I Gonzalez-Ericsson, et al.
JCI Insight|December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Pageof 36